- Home
- VSTD vs GLMD Comparison
VSTD vs GLMD Comparison
Compare VSTD & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTD | GLMD |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | Israel |
| Employees | 259 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.4M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | VSTD | GLMD |
|---|---|---|
| Price | $0.39 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.2K | ★ 4.9M |
| Earning Date | 05-04-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.41 |
| 52 Week High | $2.20 | $2.67 |
Technical Indicators
Market Signals| Indicator | VSTD | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 71.10 | 62.10 |
| Support Level | $0.31 | $0.74 |
| Resistance Level | $0.41 | $0.87 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 95.33 | 35.78 |
Price Performance
Historical ComparisonAbout VSTD Vestand Inc.
Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.